Our long-term goals are to develop clinically safe human butyrylcholinesterase (huBuChE) variants as? hydrolytic catalysts to protect populations at risk from exposure to chemical warfare agents or? organophosphate (OP) pesticides. The challenge to convert huBuChE into an OP hydrolytic catalyst is to? identify huBuChE variants that are resistant to inactivation, catalyze OP hydrolysis efficiently and rapidly and? spontaneously dephosporylate. The underlying hypothesis for our work is that combinations of huBuChE? mutations at multiple residues, close to and/or far from the active site, are needed to markedly improve the? OP hydrolysis activity to ultimately serve as a clinically useful hydrolytic catalyst. The primary goal of the? current work is to apply powerful molecular evolution strategies to produce huBuChE variants with? significantly improved hydrolytic activity for OP nerve agents.
The Aims for this research include: 1)? Stereoselective synthesis of different classes of enantiomerically pure OP model substrates for functional? screening; 2) Optimization and validation of the functional screening system with a site-saturation mutation? library; 3) Evolution of huBuChE variants with catalytic activity using two model compounds representing? tabun and soman; 4) Evolution of huBuChE variants with broad specificity; and 5) In vitro and in vivo? efficacy testing of evolved huBuChE candidates using authentic nerve agents in collaboration with the? Center. This work provides the research and development (R&D) effort required to identify OP catalytic? huBuChE variants through a combinatorial approaches including molecular evolution, rational designed? mutagenesis, in vitro and in vivo efficacy functional screening. Upon completion of this study, we will have? the third generation huBuChE products ready to enter advanced development including production under? good manufacturing practice (GMP) conditions, advanced pharmacological screening, and preclinical testing,? a process that has been successfully established to transition two generations of huBuChE based protein? drugs, human plasma derived huBuChE and recombinant wild-type huBuChE, for advanced product? development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS058183-03
Application #
7689882
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
3
Fiscal Year
2008
Total Cost
$711,414
Indirect Cost
Name
U.S. Army Medical Research Institute Chem Def
Department
Type
DUNS #
168812329
City
Aberdeen Proving Ground
State
MD
Country
United States
Zip Code
21010
Ashani, Yacov; Leader, Haim; Aggarwal, Nidhi et al. (2016) In vitro evaluation of the catalytic activity of paraoxonases and phosphotriesterases predicts the enzyme circulatory levels required for in vivo protection against organophosphate intoxications. Chem Biol Interact 259:252-256
Smith, Carl D; Wright, Linnzi K M; Garcia, Gregory E et al. (2015) Hormone-dependence of sarin lethality in rats: Sex differences and stage of the estrous cycle. Toxicol Appl Pharmacol 287:253-7
Ben-David, Moshe; Sussman, Joel L; Maxwell, Christopher I et al. (2015) Catalytic stimulation by restrained active-site floppiness--the case of high density lipoprotein-bound serum paraoxonase-1. J Mol Biol 427:1359-1374
Magliery, Thomas J (2015) Protein stability: computation, sequence statistics, and new experimental methods. Curr Opin Struct Biol 33:161-8
Schneider, Jeannine D; Castilho, Alexandra; Neumann, Laura et al. (2014) Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue. Biotechnol J 9:501-10
Rockah-Shmuel, Liat; Tawfik, Dan S; Goldsmith, Moshe (2014) Generating targeted libraries by the combinatorial incorporation of synthetic oligonucleotides during gene shuffling (ISOR). Methods Mol Biol 1179:129-37
Dwyer, Mary; Javor, Sacha; Ryan, Daniel A et al. (2014) Novel human butyrylcholinesterase variants: toward organophosphonate detoxication. Biochemistry 53:4476-87
Li, Bin; Duysen, Ellen G; Froment, Marie-Thérèse et al. (2013) Polyclonal antibody to soman-tyrosine. Chem Res Toxicol 26:584-92
Jiang, Wei; Cashman, John R; Nachon, Florian et al. (2013) Mass spectrometry method to identify aging pathways of Sp- and Rp-tabun adducts on human butyrylcholinesterase based on the acid labile P-N bond. Toxicol Sci 132:390-8
Luechapanichkul, Rinrada; Chen, Xianwen; Taha, Hashem A et al. (2013) Specificity profiling of dual specificity phosphatase vaccinia VH1-related (VHR) reveals two distinct substrate binding modes. J Biol Chem 288:6498-510

Showing the most recent 10 out of 48 publications